業績公告
即時報告
8-K
2026-05-15
aTyr Pharma 提交8-K公告第一季度財務業績
AI 繁中摘要
📄 **美國證交會8-K申報** | aTyr Pharma, Inc.（納斯達克：ATYR）
日期：2026年5月15日
aTyr Pharma 於今日發佈新聞稿，公佈截至2026年3月31日止的第一季度（2026財年Q1）財務業績。該新聞稿作為附件99.1隨本8-K提交。
關鍵要點：
- 公司管理層透過新聞稿總結季度營運表現及財務狀況，但本次申報並未在正文中披露具體數字（如收入、虧損或現金結餘）。
- 投資者應直接參閱附件新聞稿以獲取完整業績數據及管理層評論。
對投資者的潛在意義：
- 8-K僅為「提供」性質（furnished），而非「存檔」（filed），因此相關陳述不構成《1934年證券交易法》第18條下的法律責任，亦不自動納入未來申報文件。
- 對於生物科技公司aTyr Pharma而言，季度業績通常會反映研發進度（如臨床試驗）及現金消耗率，投資者需留意資金狀況與管線里程碑。
🔍 建議：查閱附件99.1以獲得全面的財務明細及2026年展望。
展開英文正文
8-K false000133997000013399702026-05-152026-05-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 10240 Sorrento Valley Road, Suite 300 San Diego, CA 92121 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (858) 731-8389 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On May 15, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information under this Item 2.02, including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 15, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATYR PHARMA, INC. By: /s/ Jill M. Broadfoot Jill M. Broadfoot Chief Financial Officer Date: May 15, 2026 3